How Long Does Peptide Therapy Take? Realistic Timelines

"How long until I notice something?" is the question almost everyone asks in their first peptide consultation. It is a fair question, and it has a frustrating answer: it depends entirely on what you are taking, and for many popular peptides nobody has measured it.

Online, peptide timelines are presented with suspicious precision: "results in week two", "full effects by day 30". Those numbers are almost never sourced. Where real timelines exist, they come from trials that followed people for months and reported averages that hide a wide range. This guide sets out what those trials show, what is simply unknown, and how a sensible treatment plan paces itself.

Why "how long?" has two very different answers

Peptides fall into two groups, and timelines work completely differently between them.

FDA-approved peptide medicines — semaglutide, tirzepatide, tesamorelin, insulin and others — were tested in randomized trials with defined durations and measured outcomes. Their labeling specifies how treatment starts and how doses change. You can point to a study and say what happened to people at 12 weeks, 26 weeks or 68 weeks.

Unapproved peptides — BPC-157, TB-500, KPV, MOTS-c and many others — mostly have animal data and, at best, small, short human studies. There is no trial that tells you when a tendon feels better on BPC-157 or when energy changes on MOTS-c, because the trials that would answer that have not been done. Any timeline you see for them is anecdote dressed as data. Our overview of what the peptide evidence shows covers this gap in detail.

What the trials actually measured

Two things jump out of that table. First, the effective treatments took months, not days. Second, the peptides with the loudest online timelines are the ones with no timeline data at all.

GLP-1 medicines: the slow start is deliberate

Semaglutide (Wegovy) and tirzepatide (Zepbound) are both started at a low dose and increased in steps, generally every four weeks, according to their labeling. For Wegovy, reaching the usual maintenance dose takes about four months. That pace exists to reduce nausea, vomiting and other gastrointestinal side effects, which are most common during dose increases.

What people often feel first is appetite change and less "food noise", sometimes within the first weeks. Weight change on the scale tends to be gradual, and the trial results everyone quotes were measured after well over a year. Plateaus are normal and expected; we cover them in the weight-loss plateau.

The other half of the timeline is what happens after stopping. In the STEP 1 trial extension, people who stopped semaglutide regained about two-thirds of the weight they had lost within a year. That is not a failure of the medicine; it reflects obesity being a chronic condition. It does mean a realistic plan talks about duration from the start. See what happens when you stop a GLP-1.

Testosterone: effects in stages

Testosterone is not a peptide, but many people consider peptides alongside it, so it is a useful comparison. The 2011 review by Saad and colleagues pulled together studies to map when different effects appear. Effects on sexual interest appeared at around three weeks and plateaued at about six. Changes in body composition became measurable at around 12 to 16 weeks. Improvements in erectile function could take up to six months. Effects on red blood cells peaked at nine to 12 months, and bone density continued to change over years.

That staging shapes monitoring. Blood tests are timed to catch the slower effects, including rising hematocrit, rather than only checking whether you feel different. Our guide to TRT risks and monitoring covers the schedule.

Tesamorelin and the growth-hormone pathway

Tesamorelin (Egrifta) is an approved analogue of growth-hormone-releasing hormone, indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its approval rested on 26-week trials measuring visceral fat on CT scans, with average reductions of around 15 percent. The trials also found that the reduction did not last once treatment stopped. Whether results in that population apply to anyone else is a separate question, covered in tesamorelin: the approved GHRH analogue and its limits.

Compounds sold as growth-hormone secretagogues without approval, such as CJC-1295 and ipamorelin, do not have comparable outcome trials establishing when, or whether, body composition changes. Their status has also been in flux; our explainer covers what is known.

Unapproved peptides: why no one can honestly give you a date

When someone tells you BPC-157 "starts working in 7 to 10 days", ask what study that comes from. The answer, almost always, is a forum, a vendor, or a clinic's own marketing. In the case of BPC-157, FDA reviewers described the available human studies, in their review for the July 2026 advisory committee meeting, as short, small and insufficient to establish safety or effectiveness. There is no basis for a timeline without an established effect.

There is also a legal dimension to the calendar. Several of these substances were voted on by FDA's Pharmacy Compounding Advisory Committee in July 2026, but a vote is not a rule, and they still could not lawfully be compounded from bulk as of this writing. A treatment plan built on a substance whose availability could change next month is not really a plan. Rules change; check current status with FDA or your clinician. The July 2026 vote, explained sets out where things stood.

What a paced plan looks like

Whatever the treatment, a responsible plan is built around review points. In our practice the shape is usually this.

1. Before starting (week 0). History, medication list, contraindication screening and, where relevant, baseline lab work. You should also learn what success would look like and what would make us stop.
2. Weeks 1–4. Tolerability, not results. Side effects, injection technique, questions. For GLP-1 medicines this is also the first dose step.
3. Weeks 4–12. Early signals: appetite, energy, sleep, pain, mood. Dose adjustments where the labeling allows. Repeat labs when indicated.
4. Months 3–6. The first honest verdict. Has anything measurable changed? If not, that is real information, and continuing out of hope is not a plan.
5. Months 6–12 and beyond. Slower outcomes, monitoring, and the question of duration: how long you stay on, what happens if you stop, and what maintenance looks like.

Some people reach the three- or six-month review and decide, with their clinician, that a treatment isn't worth continuing. That is a good outcome of a well-run plan. So is the first consultation ending with the conclusion that a peptide isn't the right tool at all. If you want to see how the first visit works, read what happens in a peptide therapy consultation, or learn about our peptide therapy consultations.

Why individual timelines vary so much

Trial averages describe groups. Within any trial, some people respond early, some late, some barely at all. Factors that commonly shift the picture include:

• Starting point. People with more to change often see larger early changes.
• Dose steps and tolerability. Pausing a dose increase for side effects lengthens the timeline, and that is fine.
• Sleep, alcohol, activity and protein intake. These affect weight, recovery and energy independently of any medicine.
• Other medicines and conditions. Thyroid disease, steroids, some antidepressants and poorly controlled diabetes can all change what you notice.
• Adherence and consistency. Missed doses and irregular schedules blur results.

Common questions

How long does peptide therapy take to work?

For approved medicines, trials ran for months: 26 weeks for tesamorelin, 68 to 72 weeks for the main semaglutide and tirzepatide obesity trials. For unapproved peptides there is no reliable human timeline, because the trials have not been done.

How soon will I notice appetite changes on a GLP-1?

Many people notice some appetite change within the first weeks, but doses are increased gradually, generally every four weeks, and weight change is usually gradual. Your prescriber and the labeling set the schedule.

If I don't see results in a month, should I stop?

Not on your own, and not necessarily. One month is too early to judge most treatments. Agree on review points with your clinician before you start, and contact them sooner if side effects are troubling you.

Do results last after stopping?

Often not fully. Trials of semaglutide and tesamorelin both found that much of the change reversed after treatment ended. Planning for duration and maintenance is part of starting well.

Can I speed things up with a higher dose?

For approved medicines, dosing follows the labeling and your prescriber's judgment; faster escalation often means more side effects. For unapproved peptides, no established dose-response exists. If you would like a plan with honest milestones, you can book a consultation.